Sign In
Buy AVTE
$2.68
+0 (+0%)
At Close: Jul 25, 2025
Aerovate Therapeutics to Explore Strategic Alternatives
08:00am, Monday, 08'th Jul 2024
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled
The 3 Hottest Stock Downgrades From Last Week
07:00am, Thursday, 27'th Jun 2024
Wall Street's leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies an
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
02:00pm, Friday, 21'st Jun 2024
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securi
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
01:22pm, Thursday, 20'th Jun 2024
Investors can contact the law firm at no cost to learn more about recovering their losses
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
10:25am, Tuesday, 18'th Jun 2024
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton
12:07pm, Monday, 17'th Jun 2024
BOSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE) for potential securities law violations. Investors who have lost money in their Ae
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistan
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
01:19pm, Tuesday, 11'th Jun 2024
Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The g
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHC
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
04:30pm, Monday, 13'th May 2024
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
04:10pm, Monday, 25'th Mar 2024
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the liv
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
08:00am, Wednesday, 06'th Mar 2024
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerov
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
08:00am, Monday, 13'th Nov 2023
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives
